BMS-986393

A Study of BMS-986393 (CC-95266) in Subjects With Relapsed and/or Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986393 (CC-95266) in participants with relapsed and/or refractory multiple myeloma (R/R MM).

Trial status

Active, Not Recruiting

Phase
Phase 1
Enrollment
75
Last Updated
1 month ago
Am I Eligible

Published Results

Explore published results and other resources associated with this clinical trial (including press releases, news articles and videos).

GPRC5D-Directed CAR T-Cell Therapy BMS-986393 Shows Potential for R/R MM

The dose-escalation, first-in-human study of BMS-986393 enrolled patients with R/RMM who had three or more prior lines of therapy. Patients received BMS-986393 at doses of 25 (six patients), 75 (nine patients), 150 (12 patients), 300 (six patients), and 450 (three patients) x 106 CAR T cells. During the dose expansion portion, 12 additional patients received 150 x 106 CAR T cells; 11 patients received 300 x 106 CAR T cells; and eight patients received 450 x 106 CAR T cells.

The majority (83.6%) of patients had grade 3-4 treatment-emergent adverse events, most commonly neutropenia (59.7%), anemia (31.3%), and thrombocytopenia (29.9%). Risk for high-grade infection was only about 15%, Dr. Bal noted. No deaths from infection occurred.

Cytokine release syndrome (CRS) of any grade occurred in 86.6% of patients. One patient had grade 5 CRS related to the study drug, and this occurred at the highest dose level.

On-target, off-tumor adverse events included any-grade skin adverse events (20.9%), dysgeusia (17.9%), nail events (9.0%), and dysphagia (1.5%). Immune effector cell-associated neurotoxicity syndrome (ICANS)-type neurotoxicity was infrequent, with a total incidence of 10.4%. Non-ICANS neurotoxicity appeared to be dose related, was mostly low grade, and showed signs of reversibility in some patients, Dr. Bal said.

The overall response (OR) rate was 86.5% in the 52 efficacy evaluable patients. The complete response (CR) rate was 38.5%, with responses occurring at all dose levels. In patients with prior BCMA-directed therapy exposure (25 patients), including CAR T cells, the OR rate was 76.0% with CR occurring in 36.0% of the patients.

All six patients who were efficacy and measurable residual disease (MRD) evaluable and had CR or better were MRD-negative at month three.

8 months ago Read more

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.